Loading clinical trials...

Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET) | Clinical Trials | Clareo Health

RECRUITINGNA

Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)

Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET): One Single Center, Safety and Feasibility Study

NCT04664933•Hui-Sheng Chen

View on ClinicalTrials.gov

Summary

To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who received recanalization operation.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥18 years;
•2. Acute ischemic stroke patients who is eligible for endovascular treatment;
•3. Signed informed consent.

Exclusion Criteria

•1. Modified Rankin Score \>2 caused by a history of prior stroke;
•2. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (\<80000/mm3);
•3. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;
•4. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);
•5. Unsuitable for this clinical studies assessed by researcher.

Locations (1)

Department of Neurology, General Hospital of Northern Theater Command

Shenyang, China

Key Dates

Start Date

December 1, 2020

Primary Completion Date

May 31, 2026

Completion Date

May 31, 2026

Last Updated

August 21, 2025

Enrollment

ESTIMATED participants

Conditions

Stroke, IschemicIntravascular ThrombosisMechanical Thrombectomy

Interventions

Intra-arterial administration of neuroprotective agents

DRUG

The Fourth Left Atrial Appendage Occlusion Study

NCT05963698

Atrial FibrillationStroke, Ischemic+1 more

View study

RECRUITINGNA

Utility of CC7 Transfer in Stroke Subtypes

NCT06001736

Stroke, IschemicStroke Hemorrhagic+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 21, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)

Inclusion Criteria

Exclusion Criteria

The Fourth Left Atrial Appendage Occlusion Study

Utility of CC7 Transfer in Stroke Subtypes

Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke

Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials

Prismatic Lenses and tDCS in Neglect

Prognostic Value of Isolated and Combined Score Aspects in Acute Ischemic Stroke